0       0

2018 Annual Sessions


OS03 - ORAL SESSION 03 - Novel Insights About Antibodies in Lung Transplantation


Apr 11, 2018 8:30am ‐ Apr 11, 2018 10:00am

Description

(13) Is the New ISHLT Criteria for Pulmonary Antibody-mediated Rejection Also a Severity Indicator?
Hannah Valantine, MD for Adam Cochrane, PharmD

(14) Risk Factors for the Development of Donor-specific Antibodies and Their Impact on Outcomes After Lung Transplantation
Kevin Tsui, MD

(15) Antibody-mediated Rejection: Should We Wait for Clinical Diagnosis?
Sean Agbor-Enoh, MD

(16) Elevated Donor-Derived Cell-Free DNA (ddcfDNA) as an Early Risk Factor for the Development and Persistence of De Novo Donor Specific HLA Antibody
Annette Jackson, PhD

(17) Important HLA and Non-HLA Pre-Transplant Determinants Associated with the Development of De Novo Donor Specific Antibody After Lung Transplantation
Aiwen Zhang, PhD

(18) Feasibility of Avoiding Higher Risk Epitope and Allele HLA Mismatch to Reduce de novo Donor Specific Antibody (dnDSA) in Lung Transplantation
Ricardo Zamel, PhD 

Speaker(s):

Tags: LTX BSTR PATH

You must be logged in and own this session in order to post comments.

Print Certificate
Review Answers
Print Transcript
Completed on: token-completed_on
Review Answers
Please select the appropriate credit type:
/
test_id: 
credits: 
completed on: 
rendered in: 
* - Indicates answer is required.
token-content

token-speaker-name
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
/
/
token-index
token-content